GlassScriptPhysician profile
Sumair Ozair
NPI 1447994371
$809.75
in general payments reported to CMS, 2019-2025
11 companies · $597 in 2025
The $597 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.32 · 2023: $25.09 · 2024: $174 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.88 |
| Education | $251.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $346.31 | 2025 | Resolute Onyx, Ffrangio |
| Philips North America LLC | $165.65 | 2025 | Ambulatory Monitoring & Diagnostics Undivided, Coronary Other |
| Esperion Therapeutics, INC. | $122.56 | 2024 | Nexletol, Nexlizet |
| Merck Sharp & Dohme LLC | $36.99 | 2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $34.48 | 2025 | Fasenra |
| Dexcom, INC. | $25.09 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $18.56 | 2024 | |
| Boston Scientific Corporation | $16.52 | 2024 | Watchman Flx |
| Exact Sciences Corporation | $16.28 | 2024 | Cologuard Collection Kit |
| Bridgebio Pharma, INC. | $13.99 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumair Ozair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.